Skip to main content

Coronavirus (COVID-19) Updates: Visitation Policies (New! 11.25.20) | How We're Keeping You Safe | Latest COVID Information

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC

Patrick M. Reagan, M.D.


Showing all 26 journal articles & 0 books available

Journal Articles

Spiegel JY, Dahiya S, Jain MD, Tamaresis JS, Nastoupil L, Jacobs MT, Ghobadi A, Lin Y, Lunning M, Lekakis LJ, Reagan P, Oluwole OO, McGuirk JP, Deol A, Goy A, Vu K, Andreadis C, Munoz J, Bennani NN, Vose J, Dorritie KA, Neelapu SS, Locke FL, Rapoport AP, Hill B, Miklos DB. "Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel." Blood.. 2020 Nov 6; Epub 2020 Nov 06.

Rodgers TD, Williams AM, Baran A, Reagan PM, Casulo C, Zent CS, Evans A, Friedberg JW, Barr PM. "Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma." Leukemia & lymphoma.. 2020 Oct 25; :1-8. Epub 2020 Oct 25.

Locke FL, Rossi JM, Neelapu SS, Jacobson CA, Miklos DB, Ghobadi A, Oluwole OO, Reagan PM, Lekakis LJ, Lin Y, Sherman M, Better M, Go WY, Wiezorek JS, Xue A, Bot A. "Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma." Blood advances.. 2020 Oct 13; 4(19):4898-4911.

Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Vu K, Andreadis C, Munoz J, Westin J, Chavez JC, Cashen A, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL. "Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2020 May 13; :JCO1902104. Epub 2020 May 13.

Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Milpied N, Fung H, Topp MS, Houot R, Beitinjaneh A, Peng W, Zheng L, Rossi JM, Jain RK, Rao AV, Reagan PM. "KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma." The New England journal of medicine.. 2020 Apr 2; 382(14):1331-1342.

Rodgers TD, Baran A, Reagan PM, Casulo C, Zent C, Evans A, Burack R, Williams AM, Friedberg JW, Barr PM. "Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma." British journal of haematology.. 2019 Dec 17; Epub 2019 Dec 17.

Thomas TS, Luo S, Reagan PM, Keller JW, Sanfilippo KM, Carson KR. "Advancing age and the risk of bleomycin pulmonary toxicity in a largely older cohort of patients with newly diagnosed Hodgkin Lymphoma." Journal of geriatric oncology.. 2019 Oct 24; Epub 2019 Oct 24.

Loh KP, Baran A, Lee CY, Alshaibani A, Rutherford SC, Hu J, Casulo C, Barr PM, Friedberg JW, Reagan PM. "Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation." Leukemia & lymphoma.. 2019 Jul 8; :1-4. Epub 2019 Jul 08.

Tomlinson SB, Sandwell S, Chuang ST, Johnson MD, Vates GE, Reagan PM. "Central nervous system relapse of systemic ALK-rearranged anaplastic large cell lymphoma treated with alectinib." Leukemia research.. 2019 May 28; 83:106164. Epub 2019 May 28.

Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS. "Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial." The Lancet. Oncology.. 2018 Nov 30; Epub 2018 Nov 30.

Williams AM, Baran AM, Casulo C, Reagan P, Friedberg JW, Helber M, Moore J, Baloga E, Zent CS, Barr PM. "Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience." Clinical lymphoma, myeloma & leukemia.. 2018 Oct 13; Epub 2018 Oct 13.

Frank MJ, Reagan PM, Bartlett NL, Gordon LI, Friedberg JW, Czerwinski DK, Long SR, Hoppe RT, Janssen RS, Candia AF, Coffman RL, Levy R. "Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma." Cancer discovery.. 2018 Oct 0; 8(10):1258-1269. Epub 2018 Aug 28.

David RJ, Baran A, Loh KP, Casulo C, Barr PM, Friedberg JW, Reagan PM. "Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma." Clinical lymphoma, myeloma & leukemia.. 2018 Aug 29; Epub 2018 Aug 29.

Rodgers TD, Reagan PM. "Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma." Expert opinion on emerging drugs.. 2018 Jun 0; 23(2):111-122. Epub 2018 Jun 06.

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY. "Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma." The New England journal of medicine.. 2017 Dec 28; 377(26):2531-2544. Epub 2017 Dec 10.

Reagan PM, Davies A. "Current treatment of double hit and double expressor lymphoma." Hematology. 2017 Dec 8; 2017(1):295-297.

Reagan PM, Friedberg JW. "Reassessment of Anti-CD20 Therapy in Lymphoid Malignancies: Impact, Limitations, and New Directions." Oncology.. 2017 May 15; 31(5):402-11.

Reagan PM, Barr PM. "Chemotherapy-free treatment in non-Hodgkin lymphoma: a steep learning curve." The Lancet. Haematology.. 2017 Apr 0; 4(4):e152-e153. Epub 2017 Mar 15.

Reagan, P.M. and J.W. Friedberg. "Poor survival with high-dose chemotherapy and autologous stem cell support in double-hit and double-expressor B-cell lymphomas. Translational Cancer Research, 2017. 6: p. S249-S253." Translational Cancer Research,. 2017; 6: S249-S253.

Reagan PM, Baran A, Kelly JL, Barr PM, Casulo C, Chengazi VU, Friedberg JW. "Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin Lymphoma." Clinical lymphoma, myeloma & leukemia.. 2016 Jun 0; 16(6):322-328.e2. Epub 2016 Apr 02.

Reagan PM, Friedberg JW. "Follicular lymphoma: first-line treatment without chemotherapy for follicular lymphoma." Current treatment options in oncology.. 2015 Jul 0; 16(7):32.

Reagan, P.M. and J.W. Friedberg. "Brentuximab vedotin for the treatment of Hodgkin's and non-Hodgkin's lymphoma." Expert Opinion on Orphan Drugs. 2015; 3(5): p. 609-618.

Reagan PM, Friedberg JW. "Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma." Future oncology.. 2015 11(10):1543-53.

Reagan P, Pani A, Rosner MH. "Approach to diagnosis and treatment of hypercalcemia in a patient with malignancy." American journal of kidney diseases : the official journal of the National Kidney Foundation.. 2014 Jan 0; 63(1):141-7. Epub 2013 Sep 08.

Janardhanan R, Henry Z, Hur DJ, Lin CM, Lopez D, Reagan PM, Rudnick SR, Koshko TJ, Keeley EC. "The snow-shoveler's ST elevation myocardial infarction." The American journal of cardiology.. 2010 Aug 15; 106(4):596-600.

Erlichman JS, Boyer AC, Reagan P, Putnam RW, Ritucci NA, Leiter JC. "Chemosensory responses to CO2 in multiple brain stem nuclei determined using a voltage-sensitive dye in brain slices from rats." Journal of neurophysiology.. 2009 Sep 0; 102(3):1577-90. Epub 2009 Jun 24.